JP2023519959A5 - - Google Patents

Info

Publication number
JP2023519959A5
JP2023519959A5 JP2022559484A JP2022559484A JP2023519959A5 JP 2023519959 A5 JP2023519959 A5 JP 2023519959A5 JP 2022559484 A JP2022559484 A JP 2022559484A JP 2022559484 A JP2022559484 A JP 2022559484A JP 2023519959 A5 JP2023519959 A5 JP 2023519959A5
Authority
JP
Japan
Prior art keywords
approximately
transdermal patch
weight
dextromethorphan
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022559484A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519959A (ja
JP7798361B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/024572 external-priority patent/WO2021202329A1/en
Publication of JP2023519959A publication Critical patent/JP2023519959A/ja
Publication of JP2023519959A5 publication Critical patent/JP2023519959A5/ja
Application granted granted Critical
Publication of JP7798361B2 publication Critical patent/JP7798361B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022559484A 2020-03-30 2021-03-29 デキストロメトルファンの経皮送達 Active JP7798361B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063001607P 2020-03-30 2020-03-30
US63/001,607 2020-03-30
PCT/US2021/024572 WO2021202329A1 (en) 2020-03-30 2021-03-29 Transdermal delivery of dextromethorphan

Publications (3)

Publication Number Publication Date
JP2023519959A JP2023519959A (ja) 2023-05-15
JP2023519959A5 true JP2023519959A5 (enExample) 2024-04-03
JP7798361B2 JP7798361B2 (ja) 2026-01-14

Family

ID=77928529

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022559484A Active JP7798361B2 (ja) 2020-03-30 2021-03-29 デキストロメトルファンの経皮送達

Country Status (10)

Country Link
US (1) US20240216358A1 (enExample)
EP (1) EP4125902A4 (enExample)
JP (1) JP7798361B2 (enExample)
KR (1) KR20220161416A (enExample)
CN (1) CN115996709A (enExample)
AU (1) AU2021249031A1 (enExample)
CA (1) CA3173322A1 (enExample)
IL (1) IL296624A (enExample)
TW (1) TW202203921A (enExample)
WO (1) WO2021202329A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12194006B2 (en) 2013-11-05 2025-01-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12109178B2 (en) 2013-11-05 2024-10-08 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12569479B2 (en) 2016-05-25 2026-03-10 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12433884B2 (en) 2020-06-05 2025-10-07 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US20250073188A1 (en) 2020-06-05 2025-03-06 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12472156B2 (en) 2020-06-05 2025-11-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
KR20230113787A (ko) 2020-12-01 2023-08-01 안테씨프 바이오벤쳐스 투 엘엘씨 우울증 환자의 자살 위험 감소를 위한 부프로피온 및덱스트로메토르판
IT202100029225A1 (it) * 2021-11-18 2023-05-18 Capietal Italia S R L Miscela comprendente un cannabidiolo CBD, un beta-cariofillene BCP e un furanodiene, per uso in un metodo di trattamento del dolore neuropatico periferico
US12156914B2 (en) 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
US12036191B1 (en) 2022-06-30 2024-07-16 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US11844797B1 (en) 2023-04-20 2023-12-19 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
US12194036B2 (en) 2022-07-07 2025-01-14 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
AU2023356341A1 (en) * 2022-10-06 2025-05-15 Shinkei Therapeutics, Inc. Transdermal delivery of dextromethorphan
CN119700641A (zh) * 2025-02-26 2025-03-28 深圳市药欣生物科技有限公司 舌下施用的右美沙芬药物组合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU702593B2 (en) * 1994-09-14 1999-02-25 Minnesota Mining And Manufacturing Company Matrix for transdermal drug delivery
SE9601528D0 (sv) * 1996-04-23 1996-04-23 Pharmacia Ab Transdermally administered dextromethorphan as antitissue agent
US5985317A (en) * 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
JP2001527554A (ja) * 1997-05-07 2001-12-25 アルゴス ファーマシューティカル コーポレーション 抗うつ薬とnmdaレセプター拮抗薬とを組み合わせる神経障害痛の治療用組成物及び治療方法
US20060223786A1 (en) * 2005-04-01 2006-10-05 Smith David J Transdermal pain control method and device
JP5666087B2 (ja) * 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Cns関連疾患の治療のための方法及び組成物
JP2011526889A (ja) * 2008-06-30 2011-10-20 アフギン ファーマ,エルエルシー 局所局部的神経作用療法
ES2528650T3 (es) * 2010-11-17 2015-02-11 Hexal Ag Sistema terapéutico transdérmico que comprende buprenorfina
TWI795446B (zh) * 2017-10-04 2023-03-11 美商神經治療股份有限公司 右旋美索芬(dextromethorphan)經皮輸送裝置
DK3784237T3 (da) * 2018-04-25 2024-01-08 Shinkei Therapeutics Inc Indretning til transdermal levering af tetrabenazin

Similar Documents

Publication Publication Date Title
JP6845162B2 (ja) ケタミン経皮送達システム
JP7798361B2 (ja) デキストロメトルファンの経皮送達
RU2408368C2 (ru) Препараты соли бупропиона с модифицированным высвобождением
JP2022060428A (ja) 経口送達と生物学的に同等である薬物動態を有する経皮送達システム
US20200030251A1 (en) Transdermal drug delivery system for ketamine
RU2007122410A (ru) Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda-рецептора, способ введения такого nmda-антагониста субъекту
US8017146B2 (en) Transdermal delivery system with two superimposed adhesive layers having different affinities to the active substance comprised
JP2002510600A (ja) メチルフェニデートで注意欠乏障害及び注意欠乏/活動亢進障害を治療する組成物及び方法
JP2022087276A (ja) メマンチン経皮送達システム
JP2003531157A (ja) オキシブチニン治療に関連した有害な経験の最小化
JP2020536953A5 (enExample)
US20120171297A1 (en) Threo-dops controlled release formulation
US9408802B1 (en) Seven day drug in adhesive transdermal delivery
CA2598406C (en) Method for a treatment with a medicament combination and medicament combinations suitable for the same
EP3522843B1 (en) Pramipexole transdermal delivery system and uses thereof
JP2022511673A (ja) 運動障害を処置するためのガボキサドール、ガナキソロンおよびアロプレグナノロンの使用
JP2022540917A (ja) 治療的処置のためのガボキサドール含有医薬製剤
TW202430177A (zh) 右旋美索芬之經皮輸送
HK40129313A (zh) 右美沙芬的经皮递送
HK40025664A (en) Transdermal drug delivery system for ketamine